Objective      To discuss the clinical treatment for patients infected with hepatitis C virus genotype 6 (HCV 6).       Methods      Pegylated interferon plus ribavirin therapy for HCV 6 infection was defined as the experimental group

and the same therapy for HCV 2/3 infection was defined as the control group. The therapy lasted for 24 weeks

and the follow-up time was more than 24 weeks. The basic data characteristics of the 2 groups were analyzed to compare their virological response effects.       Results      In the study

53 patients with HCV 6 infection and 84 patients with HCV 2/3 infection were enrolled. The rapid virological response (RVR) ratios of the patients infected with HCV 6 and HCV 2/3 were 88.7% and 89.3%

respectively

and 95% confidence interval was (-0.113 9

0.101 9). The early virological response (EVR) ratios were 94.3% and 96.4%

and 95% confidence interval was (-0.095 0

0.053 0). The sustained virological response (SVR) ratios were 86.8% and 90.5%

and 95% confidence interval was (-0.147 6

0.073 6). The positive predictive values of RVR to SVR were 89.4% and 93.3%

and 95% confidence interval was (-0.143 6

0.065 6). The positive predictive values of EVR to SVR were 88.0% and 91.4%

and 95% confidence interval was (-0.142 8

0.074 8).       Conclusion      The curative effect of pegylated interferon plus ribavirin therapy for HCV 6 infection and HCV 2/3 infection has no significant difference

so 24-week pegylated interferon plus ribavirin therapy is highly recommended to the patients infected with HCV 6.